Skip to main content
SpringerLink
Log in
Book cover

Renal Anemia pp 89–98Cite as

Are uremic inhibitors of erythropoiesis clinically relevant?

  • Chapter

  • 109 Accesses

Abstract

Among hemodialysis patients, low hematocrits contribute to an increased rate of hospitalizations as well as shortened survival [1, 2]. Consequently, it is important that clinicians identify factors that impair response to recombinant erythropoietin (EPO) and lead to persistent anemia in hemodialysis patients.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Xia H, Ebben J, Ma JZ, et al. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol. 1999;10:1309–16.

    PubMed  CAS  Google Scholar 

  2. Ma JZ, Ebben J, Xia H, et al. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10:610–19.

    PubMed  CAS  Google Scholar 

  3. Eschbach JW, Funk D, Adamson J, Kuhn J, Scribner BH, Finch CA. Erythropoiesis in patients with renal failure undergoing chronic dialysis. N Engl J Med. 1967; 276:653–8.

    Article  PubMed  Google Scholar 

  4. Macdougall IC. Role of uremic toxins in exacerbating anemia in renal failure. Kidney Int. 2001;59:S67–72.

    Article  Google Scholar 

  5. Wallner SF, Vautrin RM. Evidence that inhibition of erythropoiesis is important in the anemia of chronic renal failure. J Lab Clin Med. 1981;97:170–8.

    PubMed  CAS  Google Scholar 

  6. Markson JL, Rennie JB. The anemia of chronic renal insufficiency. Scottish Med J. 1956;1:320–2.

    CAS  Google Scholar 

  7. Radtke HW, Rege AB, LaMarche MB, Bartos D, Campbell RA, Fisher JW. Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. J Clin Invest. 1981;67:1623–9.

    Article  PubMed  CAS  Google Scholar 

  8. Essers U, Muller W, Heintz R. Effect of erythropoietin in normal men and in patients with renal insufficiency. Proc Eur Dial Transplant Assoc. 1974;11:398–402.

    CAS  Google Scholar 

  9. Saito A, Suzuki I, Chung TG, et al. Separation of an inhibitor of erythropoiesis in “middle molecules” from hemodialysate from patients with chronic renal failure. Clin Chem. 1986;32:1938–41.

    PubMed  CAS  Google Scholar 

  10. Ortega JA, Malekzadeh MH, Dukes PP, Ma A, Pennisi AV, Fine RN, Shore NA. Exceptionally high serum erythropoietin activity in an anephric patient with severe anemia. Am J Hematol. 1977;2:299–306.

    Article  PubMed  CAS  Google Scholar 

  11. Kushner D, Beckman B, Nguyen L, et al. Polyamines in the anemia of end-stage renal disease. Kidney Int. 1991;39:725–32.

    Article  PubMed  CAS  Google Scholar 

  12. Delwiche F, Segal GM, Eschbach JW, et al. Hematopoietic inhibitors in chronic renal failure: lack of in vitro specificity. Kidney Int. 1986;29:641–8.

    Article  PubMed  CAS  Google Scholar 

  13. McGonigle RJS, Husserl F, Wallin JD, Fisher JW. Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure. Kidney Int. 1984;25:430–6.

    Article  PubMed  CAS  Google Scholar 

  14. Zappacosta AR, Caro J, Erlev A. Normalization of hematocrit in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis. Am J Med. 1982;72:53–7.

    Article  PubMed  CAS  Google Scholar 

  15. Urabe A, Chiba S, Kosaka K, et al. Response of uremic bone marrow cells to erythropoietin in vitro. Scand J Haematol. 1976;17:335–40.

    Article  PubMed  CAS  Google Scholar 

  16. Santiago GC, Rao TKS, Laird NM. Effect of dialysis therapy on the hematopoietic system: The National Cooperative Dialysis Study. Kidney Int. 1983;23:S95-S100.

    Google Scholar 

  17. Geerlings W, Morris RW, Brunner FP, et al. Factors influencing anemia in dialysis patients. A special survey by the EDTA-ERA Registry. Nephrol Dial Transplantation. 1993;8:585–9.

    CAS  Google Scholar 

  18. Koch KM, Patyna WD, Shaldon S, Werner E. Anemia of the regular hemodialysis patient and its treatment. Nephron. 1974;12:405–19.

    Article  PubMed  CAS  Google Scholar 

  19. Yang CS, Chen SW, Chiang CH, et al. Effects of increasing dialysis dose on serum albumin and mortality in hemodialysis patients. Am J Kidney Dis. 1996;27:380–6.

    Article  CAS  Google Scholar 

  20. Frankenfield D, Johnson CA, Wish JB, Rocco MV, Madore F, Owen WF Jr, for the ESRD Core Indicators Workgroup. Anemia management of adult hemodialysis patients in the U.S.: results from the 1997 ESRD core indicators project. Kidney Int. 2000;57:578–89.

    Article  PubMed  CAS  Google Scholar 

  21. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med. 1996; 334:420–5.

    Article  PubMed  CAS  Google Scholar 

  22. McClellan WM, Frankenfield DL, Wish JB, et al. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: results from the 1998 end-stage renal disease core indicators project. Am J Kidney Dis. 2001;37:E36.

    Article  PubMed  CAS  Google Scholar 

  23. Madore F, Lowrie E, Brugnara C, et al. Anaemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol. 1997;8:1921–9.

    PubMed  CAS  Google Scholar 

  24. Ifudu O, Uribarri J, Rajwani I, Vlacich V, Reydel K, Delosreyes G, Friedman EA. Adequacy of dialysis and differences in hematocrit among dialysis facilities. Am J Kidney Dis. 2000;36:1166–74.

    Article  PubMed  CAS  Google Scholar 

  25. National Kidney Foundation-Dialysis Outcomes Quality Initiative (NKF-DOQI) Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. Am J Kidney Dis. 1997;30:S192-S237.

    Google Scholar 

  26. Health Care Financing Administration. 1998 Annual Report, End Stage Renal Disease Core Indicators Project. Department of Health and Human Services, Health Care Financing Administration, Office of Clinical Standards and Quality, Baltimore, Maryland, December, 1998.

    Google Scholar 

  27. Cotter JC, Thamer M, Kimmel PL, et al. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990–1996. Kidney Int. 1998;54:2129–39.

    Article  PubMed  CAS  Google Scholar 

  28. Cohen D, Raja RM. Erythropoietin requirements remain high in erythropoietin resistant patients after iron repletion. ASAIO J. 1998;44:M596–7.

    Article  PubMed  CAS  Google Scholar 

  29. Ifudu O, Friedman EA. Economic implications of inadequate response to erythropoietin in patients with end-stage renal disease. Dial Transplantation. 1997;26:664–9.

    Google Scholar 

  30. Allen DA, Breen C, Yaqoob MM, Macdougall IC. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. J Invest Med. 1999;47:204–11.

    CAS  Google Scholar 

  31. Opatrna S, Opatrny K, Jr, Cejkova’ P, et al. Relationship between anemia and adequacy of continuous ambulatory peritoneal dialysis. Nephron. 1997;77:359–60.

    Article  PubMed  CAS  Google Scholar 

  32. Tzamaloukas AH, Murata GH, Sena P. When do plasma levels of azotemic indices indicate inadequacy of peritoneal dialysis? Nephron. 1994;67:495–6.

    Article  PubMed  CAS  Google Scholar 

  33. Ifudu O, Friedman EA. Effect of increased hemodialysis dose on endogenous erythropoietin production in end-stage renal disease. Nephron. 1998;79:50–4.

    Article  PubMed  CAS  Google Scholar 

  34. Movilli E, Cancarini GC, Zani R, Camerini C, et al. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol Dial Transplantation. 2001;16:111–4.

    Article  CAS  Google Scholar 

  35. Scaini P, Sandrini M, Zani R, et al. Adequacy reduces erythropoietin dose in peritoneal dialysis patients [Abstract]. Nephrol Dial Transplantation. 1999;14: A258.

    Article  Google Scholar 

  36. Depner TA, Rizwan S, James LA. Effectiveness of low dose erythropoietin: a possible advantage of high flux hemodialysis. ASAIO Trans, 1990;36:M223–5.

    PubMed  CAS  Google Scholar 

  37. Locatelli F, Andrulli S, Pecchini F, Pedrini L, et al. Effect of high-flux dialysis on the anaemia of haemodialysis patients. Nephrol Dial Transplantation. 2000;15: 1399–409.

    Article  CAS  Google Scholar 

  38. Naets JP, Garcia JF, Tousaaint C, Buset M, Waks D. Radioimmunoassay of erythropoietin in chronic uremic or anephric patients. Scand J Haematol. 1986; 37:390–4.

    Article  PubMed  CAS  Google Scholar 

  39. Kato A, Hishida A, Kumagai H, Furuya R, Nakajima T, Honda N. Erythropoietin production in patients with chronic renal failure. Renal Failure. 1994;16:645–51.

    Article  PubMed  CAS  Google Scholar 

  40. Morris K, Coulthard M. End-stage kidneys are capable of increased erythropoietin production. Pediatr Nephrol. 1993;7:273–5.

    Article  PubMed  CAS  Google Scholar 

  41. Walle AJ, Wong GY, Clemons GK, Garcia JF, Niedermayer W. Erythropoietinhematocrit feedback circuit in the anemia of end-stage renal disease. Kidney Int. 1987;31:1205–9.

    Article  PubMed  CAS  Google Scholar 

  42. Chandra M, Miller ME, Garcia JF, Mossey RT, McVicar M. Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients. Nephron. 1985;39:26–9.

    Article  PubMed  CAS  Google Scholar 

  43. Ifudu O, Fowler A. Hepatitis B virus infection and the response to erythropoietin in end-stage renal disease. ASAIO J. 2001;47:569–72.

    Article  PubMed  CAS  Google Scholar 

  44. Chan N, Barton CH, Mirahmadi MS, et al. Erythropoiesis associated with viral hepatitis in end-stage renal disease. Am J Med Sci. 1984;287:56–8.

    Article  PubMed  CAS  Google Scholar 

  45. Shaw AB. Hemolysis in chronic renal failure. Br Med J. 1967;2:213–16.

    Article  PubMed  CAS  Google Scholar 

  46. Hartitzsch BV, Carr D, Kjellstrand CM, Kerr DNS. Normal red cell survival in well dialyzed patients. Trans ASAIO. 1973;19:471–4.

    Article  Google Scholar 

  47. Najean Y, Moynot A, Deschryver F, Zins B, Naret C, Jacquot C, Drueke T. Kinetics of erythropoiesis in dialysis patients receiving recombinant erythropoietin. Nephrol Dial Transplantation. 1989;4:350–5.

    CAS  Google Scholar 

  48. Muirhead N, Cattran DC, Zaltzman J, et al. Safety and efficacy of recombinant human erythropoietin in correcting the anemia of patients with chronic renal allograft dysfunction. J Am Soc Nephrol. 1994;5:1216–22.

    PubMed  CAS  Google Scholar 

  49. Sun CH, Ward HJ, Paul WL, et al. Serum erythropoietin levels after renal transplantation. N Engl J Med. 1989;321:151–7.

    Article  PubMed  CAS  Google Scholar 

  50. Wolff M, Jelkmann W. Erythropoiesis and erythropoietin levels in renal transplant recipients. Klin Wochenschr. 1991;69:53–8.

    Article  PubMed  CAS  Google Scholar 

  51. Lee DB. Interrelationship between erythropoietin and erythropoiesis: insights from renal transplantation. Am] Kidney Dis. 1991;18:54–6.

    CAS  Google Scholar 

  52. Ifudu O. Parenteral iron: pharmacology and clinical use. Nephron. 1998;80: 249–56.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Onyekachi Ifudu
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Inpatient Dialysis Services, SUNY Downstate Medical Center, Brooklyn, New York, USA

    Onyekachi Ifudu (Associate Professor of Medicine, Director) (Associate Professor of Medicine, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Ifudu, O. (2002). Are uremic inhibitors of erythropoiesis clinically relevant?. In: Ifudu, O. (eds) Renal Anemia. Springer, Dordrecht. https://doi.org/10.1007/978-94-015-9998-6_9

Download citation

  • DOI: https://doi.org/10.1007/978-94-015-9998-6_9

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-6045-7

  • Online ISBN: 978-94-015-9998-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation